Key Inclusion Criteria:

          1. Age ≥18 years old with advanced or metastatic stage solid tumors

          2. Eastern Cooperative Oncology Group (ECOG) status ≤ 1 and measurable disease per RECIST
             V1.1 (except for participants in dose escalation and prostate cancer participants)

          3. Additional inclusion criteria for dose expansion cohorts:

        Participants with homologous recombination deficiency (HRD+) or known BRCA mutant Ovarian
        cancer

        a. Previously received at least 1 line of platinum containing chemotherapy and No
        progression or recurrent disease in 6 months from last platinum containing regimen.
        Participants with HRD+ or known breast cancer susceptibility gene (BRCA) mutant
        Triple-Negative Breast Cancer

        a. 0 - 1 prior platinum-containing regimen (any treatment setting) and received ≤ 3 prior
        regimens (advanced or metastatic setting).

        Participants with HRD+ or known BRCA mutant Prostate cancer

          1. Chemotherapy-naïve or previously received ≤2 taxane-based regimens.

          2. May have pre-or post-treatment with a novel androgen receptor targeted agent.
             Participants Small cell lung and gastric cancer

        a. Previously received ≤ 2 prior lines of therapy. Participants with HRD+ NSCLC, head and
        neck cancer, esophageal cancer and soft tissue sarcomas

          1. Must have tumors with with HRD+ as centrally determined

          2. Must have received at least 1 but not more than 3 prior lines of therapy.

        Treatment naïve patients with soft tissue sarcoma might be allowed if standard of care
        therapy is not suitable or available.

        Key Exclusion Criteria: All participants

          1. Prior exposure to a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor.

          2. Refractory to platinum-based therapy.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.